or Try an Advanced Search...

    Antineoplastic Drugs Stocks List

    Symbol Grade Name % Change
    BYSI F BeyondSpring, Inc. 1.75
    STRO F Sutro Biopharma, Inc. -5.24
    CRDF F Cardiff Oncology, Inc. -1.19
    CLRB F Cellectar Biosciences, Inc. 1.28
    HURA F TuHURA Biosciences, Inc. 1.82
    BFRI F Biofrontera Inc. -2.68
    BNOX F Bionomics Limited -1.56
    PPBT F Purple Biotech Ltd. 2.83
    APLM F Apollomics Inc. -32.58
    SNDX F Syndax Pharmaceuticals, Inc. -2.19
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Cancer Clinical Medicine Medicine Cancer Treatment Biopharmaceutical Chemotherapy Advanced Solid Tumors Oncology Solid Tumors Targeted Therapy Acute Myeloid Leukemia Cancer Therapies Checkpoint Inhibitor Drugs Immune System Leukemia Lung Cancer Lymphoma Milatuzumab Non Small Cell Lung Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Antineoplastic Drugs stocks.

    Symbol Grade Name Weight
    JFWD B Jacob Funds Inc. Jacob Forward ETF 2.78
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.47
    CNCR F Loncar Cancer Immunotherapy ETF 1.34
    SBIO C ALPS Medical Breakthroughs ETF 0.93
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.66
    View all Antineoplastic Drugs ETFs...
    Compare ETFs
    Compare CNCR to SBIO Compare SURI to BBC Compare SURI to SBIO

        Antineoplastic Drugs Stocks Recent News

        Date Stock Title
        Nov 21 APLM Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 19 CLRB Q3 2024 Cellectar Biosciences Inc Earnings Call
        Nov 18 BNOX Bionomics files for $100M mixed securities shelf
        Nov 18 STRO Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
        Nov 18 CLRB Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
        Nov 18 CLRB Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03
        Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
        Nov 18 CLRB Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
        Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
        Nov 18 CLRB Earnings Scheduled For November 18, 2024
        Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
        Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
        Nov 15 CLRB Cellectar Biosciences Q3 2024 Earnings Preview
        Nov 15 PPBT Purple Biotech GAAP EPS of -$0.39
        Nov 15 PPBT Purple Biotech Reports Third Quarter 2024 Financial Results
        Nov 15 STRO Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Nov 15 BFRI Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Cancer Clinical Medicine Medicine Cancer Treatment Biopharmaceutical Chemotherapy Oncology Advanced Solid Tumors Lung Cancer Solid Tumors Targeted Therapy Acute Myeloid Leukemia Breast Cancer Checkpoint Inhibitor Drugs Immune System Leukemia Non Small Cell Lung Cancer Non Small Cell Lung Carcinoma Occupational Safety And Health
        Antineoplastic Drugs

        Antineoplastic drugs, also known as cytotoxic drugs, are a type of medication used to treat cancer. They work by interfering with the growth and spread of cancer cells. These drugs can be used alone or in combination with other treatments, such as surgery, radiation therapy, or hormone therapy.

        Browse All Tags